Riskpilot← Back to searchSign inGet full accessGemvik Medical Consulting AB
ABActiveOrg 5591674311Ryttarvägen 7General medical practice activities · NACE 8621Est. 20181 employees
Revenue 2025
SEK 323K
+25% vs 2024
EBITDA margin
92.5%
+29% vs 2024
Equity ratio
—
Financial strength
Net profit 2025
SEK 283K
+55% vs 2024
| Revenue | SEK 323K | +25% |
| EBITDA | SEK 299K | +29% |
| Net profit | SEK 283K | +55% |
| Total assets | SEK 728K | +88% |
| Equity | SEK 0 | -100% |
| Employees | 1 | — |
Legal name
Gemvik Medical Consulting AB
Org number
5591674311
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
7 augusti 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget skall driva verksamhet inom hälso- och sjukvård i form av uthyrning av läkartjänster och medicinsk kompetens, detta även innefattande utbildning och föreläsningar inom hälsa och medicinska områden, och därmed jämförlig verksamhet. Verksamhet skall även innefatta konstnärlig produktion och framställan, i såväl digital som fysisk form, och därmed jämförlig verksamhet
Address
Ryttarvägen 7
Email
axelgemvik@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 90 | 148 | 201 | 259 | 323 |
| Staff expenses | — | — | — | — | −3 |
| EBITDA | 83 | 131 | 148 | 232 | 299 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 83 | 131 | 148 | 232 | 299 |
| Net financials | — | — | — | — | 58 |
| Profit before tax | 64 | 98 | 111 | 231 | 357 |
| Tax | −11 | −20 | −23 | −48 | 74 |
| Net profit | 53 | 78 | 88 | 183 | 283 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 133 | 261 | 390 | 387 | 728 |
| Equity | 105 | 183 | 271 | 254 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 | 27 | 31 | 45 | 103 |
| Total debt | 10 | 27 | 31 | 45 | 103 |
EBITDA margin
92.5%
This company
15.8%
Market median
+485% vs market
20212025
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20212025
Return on equity
28328300.0%
This company
18.4%
Market median
+153958052% vs market
20212025
Net profit margin
87.6%
This company
8.1%
Market median
+981% vs market
20212025
Asset turnover
0.44×
This company
1.12×
Market median
-61% vs market
20212025
Debt / equity
728121.00×
This company
0.62×
Market median
-117438771% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Gemvik Medical Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Else Birgitta Lönnquist Gemvik | Deputy Board Member | 0 companies |
| Carl Axel Elion Gemvik | Board of Directors | 0 companies |